CAR-T therapy in Second-Line Setting in LBCL

September 1, 2022

Video

Lymphoma physicians from John Theurer Cancer Center comment on the use of CAR T-cell therapy in large B-cell lymphoma and the implications of clinical trial data in this setting.

EP: 1.Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL

EP: 2.Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL

Now Viewing

EP: 3.CAR-T therapy in Second-Line Setting in LBCL

EP: 4.Managing Toxicities Associated with CAR-T Therapy in LBCL

EP: 5.Brexucabtagene Autoleucel in Mantle Cell Lymphoma

EP: 6.CAR-T Therapies in the Follicular Lymphoma Treatment Landscape

EP: 7.Role of CAR-T Therapies in Acute Lymphoblastic Lymphoma

EP: 8.Recent Updates on CAR-T Therapies in Chronic Lymphocytic Leukemia

EP: 9.Next Generation of CAR-T Therapies in Lymphoma

EP: 10.Future Perspectives on CAR-T Therapies in Lymphoma

EP: 11.Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!